Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +85

Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?

Clinical trial results Drug approval AI-generated analysis

πŸ“ˆ Moderna stock jumped 174.98% in Q3 following a successful Phase 3 trial for its melanoma combination therapy.

βœ… The Intismeran Autogene and Merck Keytruda combo met primary and secondary endpoints for recurrence-free and distant metastasis-free survival.

πŸ”¬ This marks the first positive Phase 3 readout for an mRNA-based cancer treatment combined with individualized neoantigen therapy.

πŸ’° Successful trials indicate strong revenue growth prospects for Moderna in the near future due to the large melanoma market.

πŸ“… Moderna is scheduled to join the Nasdaq-100 index on Friday, October 9, potentially driving further stock price appreciation.

πŸ’‰ The FDA approved updated Spikevax and mNEXSPIKE COVID-19 vaccine formulas for the 2026-2027 seasons.

πŸ‘Ά New COVID-19 vaccine approvals expand eligibility to children aged 6 months to 64 with underlying conditions and all adults over 65.

🦠 Moderna's mRNA technology has proven effective in both oncology and infectious disease prevention pipelines.

Bullish Signals
  • Moderna stock surged 174.98% in Q3 following a landmark Phase 3 clinical trial success for its melanoma combination therapy.
  • The company achieved the first positive readout from a Phase 3 trial combining mRNA-based cancer treatment with individualized neoantigen therapy, demonstrating clinically meaningful improvement over Keytruda alone.
  • FDA approval was granted for updated Spikevax and mNEXSPIKE COVID-19 vaccine formulas for the 2026 to 2027 seasons, expanding eligibility to younger children and high-risk adults.
  • The successful melanoma trial results point to significant revenue growth prospects for Moderna in the coming years due to the huge addressable market for skin cancer treatments.
  • Moderna is set to join the Nasdaq-100 index on October 9, which may trigger portfolio rebalancing by institutional investors and funds mirroring the index composition.
Full Analysis
Moderna Inc. (NASDAQ:MRNA) shares surged approximately 175% in the third quarter, driven by a landmark Phase 3 clinical trial success for its combined therapy candidate targeting melanoma. The combination of Moderna's Intismeran Autogene and Merck's Keytruda met both primary and secondary endpoints regarding recurrence-free and distant metastasis-free survival, marking the first positive readout for an mRNA-based cancer treatment combined with individualized neoantigen therapy to demonstrate clinically meaningful improvement over Keytruda alone. The successful trial results point to significant revenue growth prospects for Moderna in the coming years, leveraging the huge addressable market for melanoma treatments. Melanoma remains a critical focus area, with global diagnoses reaching 330,000 cases in 2022 and expected case increases projected for the current year. This breakthrough validates the efficacy of mRNA technology in oncology beyond infectious diseases. In addition to its cancer pipeline, Moderna secured FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccine formulas intended for the 2026 to 2027 seasons. The new formulations expand eligibility to include children aged 6 months to 64 years with underlying conditions and all adults aged 65 and older, addressing high-risk demographics. Concurrently, Moderna is set to join the Nasdaq-100 index on October 9, replacing Warner Bros. Discovery, which may trigger further portfolio rebalancing by institutional investors.